Mayo Clinic researchers have developed methods and materials for treating cancer through the use of antigen combinations. For example, Vesicular Stomatitis Virus (VSV) vectors designed to express a GNAQ antigen, a TYRP1 anti-gen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal. In some cases, VSV vectors designed to express a BRAF antigen, a TOPO-lla antigen, and a YB-I antigen can be used to reduce the number of cancer cells within a mammal. The composition can comprise less than 100 separate nucleic acid molecules.
Development and Use of Naturally Mutated Proteins as Vaccines for the Treatment of CancersTechnology #2012-209
Questions about this technology? Ask a Technology Manager
- Jose S. Pulido M.D., M.S., M.B.A.
- Richard G. Vile Ph.D.
- Jill M. Thompson
- Christine Marie Pulido
- Timothy J. Kottke
- Rosa Maria Diaz
- Managed By
- Panya Taysavang
- Patent Protection
- US Patent Pending US 2017/0080065 A1
- PCT Patent Application WO 2015/143221 A1